The pharmaceutical industry is ripe for the picking for income investors. That's because the industry enjoys particularly high profit margins, which can fund generous dividends. But as is the case with anything good, there are still risks.

In pharmaceuticals, the biggest risk is the patent expiration of top-performing drugs. This is why it is crucial to pick pharmaceutical companies with deep product pipelines to keep revenue moving higher.

AbbVie (NYSE: ABBV) appears to fit this profile. Here's why yield-hungry investors should consider buying the Dividend King with a track record of 51 consecutive years of dividend hikes. 

Continue reading

Source Fool.com